Serous and mucinous ovarian tumors express different profiles of MMP-2,-7,-9, MT1-MMP, and TIMP-1 and -2

International Journal of Oncology

Volumn 33, Issue 6, 2008, Pages 1239-1246

  Brun, Jean Luc ^a   Cortez, Annie ^a   Commo, Frédéric ^a   Uzan, Serge ^a,b   Rouzier, Roman ^a,b   Daraï, Emile ^a,b  

^a HÔPITAL TENON   (France)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

Immunohistochemistry; MMP; Mucinous; Ovarian neoplasms; Serous; Tissue microarray

Indexed keywords

GELATINASE A; GELATINASE B; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; MMP14 PROTEIN, HUMAN; MMP2 PROTEIN, HUMAN; MMP7 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MUCINOUS OVARY TUMOR; OVARY TUMOR; PRIORITY JOURNAL; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; SEROUS OVARY TUMOR; TISSUE DIFFERENTIATION; TISSUE DISTRIBUTION; TISSUE MICROARRAY; TISSUE SPECIFICITY; TUMOR CLASSIFICATION; TUMOR DIFFERENTIATION; ADOLESCENT; CHEMISTRY; CLUSTER ANALYSIS; COMPARATIVE STUDY; CYSTADENOMA; ENZYMOLOGY; MIDDLE AGED; PATHOLOGY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CLUSTER ANALYSIS; CYSTADENOMA, MUCINOUS; CYSTADENOMA, SEROUS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 7; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MIDDLE AGED; OVARIAN NEOPLASMS; TISSUE ARRAY ANALYSIS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; YOUNG ADULT;

EID: 59049090760     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000114     Document Type: Article

References (48)

1. Hulboy DL, Rudolph LA and Matrisian LM: Matrix metalloproteinases as mediators of reproductive function. Mol Hum Reprod 3: 27-45, 1997.
2. Salamonsen LA and Nie G: Proteases at the endometrialtrophoblast interface: their role in implantation. Rev Endocr Metab Disord 3: 133-143, 2002.
3. Xue M, Le NT and Jackson CJ: Targeting matrix metalloproteases to improve cutaneous wound healing. Expert Opin Ther Targets 10: 143-155, 2006.
4. Chantrain CF, Henriet P, Jodele S, et al: Mechanisms of pericyte recruitment in tumour angiogenesis: a new role for metalloproteinases. Eur J Cancer 42: 310-318, 2006.
5. Curran S and Murray IG: Matrix metalloproteinases in tumour invasion and metastasis. J Pathol 189: 300-308, 1999.
6. Deryugina EI and Quigley JP: Matrix metalloproteinases and metastasis. Cancer Metastasis Rev 25: 9-34, 2006.
7. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM and Shafie S: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284: 67-68, 1980.
8. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA and Goldberg GI: Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane protease. J Biol Chem 270: 5331-5338, 1995.
9. Giannelli G, Falk-Marzillier J, Schiraldi O, Stetler-Stevenson WG and Quaranta V: Induction of cell migration by matrix metalloproteinase-2 cleavage of laminin-5. Science 277: 225-228, 1997.
10. Seiki M: Membrane-type 1 matrix metalloproteinase: a key enzyme for tumor invasion. Cancer Lett 194: 1-11, 2003.
11. Sounni NE and Noel A: Membrane type-matrix metalloproteinases and tumor progression. Biochimie 87: 329-342, 2005.
12. Pyke C, Ralfkiaer E, Tryggvason K and Dano K: Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer. Am J Pathol 142: 359-365, 1993.
13. Lokeshwar BL, Selzer MG, Block N and Gunja-Smith Z: Secretion matrix metalloproteinases and their inhibitors (tissue inhibitor of metalloproteinases) by human prostate in explant cultures: reduced tissue inhibitor of metalloproteinase secretion by malignant tissues. Cancer Res 53: 4493-4498, 1993.
14. Sakata K, Shigemasa K, Nagai N and Ohama K: Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary. Int J Oncol 17: 673-681, 2000.
15. Wang FQ, So J, Reierstad S and Fishman DA: Matrilysin (MMP-7) promotes invasion of ovarian cancer cells by activation of progelatinase. Int J Cancer 114: 19-31, 2005.
16. Graesslin O, Cortez A, Fauvet R, Lorenzato M, Birembaut P and Darai E: Metalloproteinase-2, -7 and -9 and tissue inhibitor of metalloproteinase-1 and -2 expressions in normal, hyperplastic and neoplastic endometrium: a clinical-pathological correlation study. Ann Oncol 17: 637-645, 2006.
17. Määttä M, Santala M, Soini Y, Talvensaari-Mattila A and Turpeenniemi-Hujanen T: Matrix metalloproteinases 2 and 9 and their tissue inhibitors in low malignant potential ovarian tumors. Tumour Biol 25: 188-192, 2004.
18. Kim TJ, Rho SB, Choi YL, et al: High expression of tissue inhibitor of metalloproteinase-2 in serous ovarian carcinomas and the role of this expression in ovarian tumorogenesis. Hum Pathol 37: 906-913, 2006.
19. Shigemasa K, Tanimoto H, Sakata K, et al: Induction of matrix metalloprotease-7 is common in mucinous ovarian tumors including early stage disease. Med Oncol 17: 52-58, 2000.
20. Benedet JL, Bender H, Jones H III, Ngan HYS and Pecorelli S: FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynecol Obstet 70: 209-262, 2000.
21. Kononen J, Bubendorf L, Kallioniemi A, et al: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4: 844-847, 1998.
22. Skacel M, Skilton B, Pettay JD and Tubbs RR: Tissue microarrays: a powerful tool for high-throughput analysis of clinical specimen: a review of the method with validation data. Appl Immunohistochem Mol Morphol 10: 1-6, 2002.
23. Budwit-Novotny DA, McCarty KS, Cox EB, et al: Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. Cancer Res 46: 5419-5425, 1986.
24. Eisen MB, Spellman PT, Brown PO and Botstein D: Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 95: 14863-14868, 1998.
25. Liu CL, Prapong W, Natkunam Y, et al: Software tools for high-throughput analysis and archiving of immunohistochemistry staining data obtained with TMAs. Am J Pathol 161: 1557-1565, 2002.
26. Makretsov NA, Huntsman DG, Nielsen TO, et al: Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma. Clin Cancer Res 10: 6143-6151, 2004.
27. Sorlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869-10874, 2001.
28. Rouzier R, Perou CM, Symmans WF, et al: Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11: 5678-5685, 2005.
29. Feeley KM and Wells M: Precursor lesions of ovarian epithelial malignancy. Histopathology 38: 87-95, 2001.
30. Tresserra F, Grases PJ, Labatisda R and Ubeda A: Histological features of the contralateral ovary in patients with unilateral ovarian cancer: a case control study. Gynecol Oncol 71: 437-441, 1998.
31. Werness BA, Afify AM, Bielat KL, Eltabbakh GH, Piver MS and Paterson JM: Altered surface and cyst epithelium of ovaries removed prophylactically from women with a family history of ovarian cancer. Hum Pathol 30: 151-157, 1999.
32. Fauvet R, Dufournet C, Poncelet. C, Uzan C, Hugol D and Darai E: Expression of pro-apoptotic (p53, p21, bax, bak and fas) and anti-apoptotic (bcl-2 and bcl-x) proteins in serous versus mucinous borderline ovarian turnouts. J Surg Oncol 92: 337-343, 2005.
33. Afzal S, Lalani EN, Poulsorn R, et al: MTI-MMP and MMP-2 mRNA expression in human ovarian tumors: possible implications for the role of desmoplastic fibroblasts. Hum Pathol 29: 155-165, 1998.
34. Wu M, Xu G, Xi L, et al: Down-regulation of MT1-MMP expression suppresses tumor cell invasion in metastatic human SW626 ovarian cancer cells. Oncol Rep 15: 501-505, 2006.
35. Sodek KL, Ringuette MJ and Brown TJ: MT1-MMP is the critical determinant of matrix degradation and invasion by ovarian cancer cells. Br J Cancer 97: 358-367, 2007.
36. Sillanpää SM, Antilla MA, Vouttlainen KA, et al: Prognostic significance of matrix metalloproteinase-7 in epithelial ovarian cancer and its relation to β-catenin. Int J Cancer 119: 1792-1799, 2006.
37. Behrens P, Rothe M, Florin A, Wellman A and Wernert N: Invasive properties of serous human epithelial ovarian tumors are related to Ets-1, MMP-1 and MMP-9 expression. Int J Mol Med 8: 149-154, 2001.
38. Ozalp S, Tanir HM, Yalcin OT, Kabukcuoglu S, Oner U and Uray M: Prognostic value of matrix metalloproteinase-9 (gelafinase B) expression in epithelial ovarian tumors. Eur J Gynaecol Oncol 24: 417-420, 2003.
39. Zhou HY, Pon YL and Wong AS. Synergistic effects of epidermal growth factor and hepatocyte growth factor on human ovarian cancer cell invasion and migration: role of extracellular signal-regulated kinase 1/ 2 and p38 mitogen-activated protein kinase. Endocrinology 148: 5195-5208, 2007.
40. Cowden Dahl KD, Zeineldin R and Hudson LG: PEA3 is necessary for optimal epidermal growth factor receptor-stimulated matrix metalloproteinase expression and invasion of ovarian tumor cells. Mol Cancer Res 5: 413-421, 2007.
41. Symowicz J, Adley BP, Gleason KJ, et al: Engagement of collagen-binding integrins promotes matrix metalloproteinase-9-dependent E-cadherin ectodomain shedding in ovarian carcinoma cells. Cancer Res 67: 2030-2039, 2007.
42. Darai E, Scoazec JY, Walker-Combrouze F, et al: Expression of cadherins in benign, borderline, and malignant ovarian epithelial tumors: a clinicopathological study of 60 cases. Hum Pathol 28: 922-928, 1997.
43. Westerlund A, Apaja-Sarkkinen M, Höyhtyä M, Puistola U and Turpeenniemi-Hujanen T: Gelatinase A-immunoreactive protein in ovarian lesions: prognostic value in epithelial ovarian cancer. Gynecol Oncol 75: 91-98, 1999.
44. Wu X, Li H, Kang L, Wang W and Shan B: Activated matrix metalloproteinase-2: a potential marker of prognosis for epithelial ovarian cancer. Gynecol Oncol 84: 126-134, 2002.
45. Schmalfeldt B, Prechtel D, Härting K, et al: Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian carcinoma. Clin Cancer Res 7: 2396-2404, 2001.
46. Qi Cai K, Yang WL, Capo-Chichi CD, et al: Prominent expression of metalloproteinases in early stages of ovarian tumorigenesis. Mol Carcinog 46: 130-143, 2007.
47. Chesler L, Golde DW, Bersch N and Johnson MD: Metallo-proteinase inhibition and erythroid potentiation are independent activities of tissue inhibitor of metalloproteinases-1. Blood 86: 4506-4515, 1995.
48. Hofmann UB, Houben R, Bröcker EB and Becker JC: Role of matrix metalloproteinases in melanoma cell invasion. Biochimie 87: 307-314, 2005.